讓抗癌藥物更精準！中國醫大團隊開發雙重標靶奈米療法，開啟癌症免疫化療新方向
日期：2026-10-27
資料來源：研究亮點｜李瑋、陳三元、鄭隆賓、徐偉成、江智聖等研究團隊
分享：
讓抗癌藥物更精準！中國醫大團隊開發雙重標靶奈米療法，開啟癌症免疫化療新方向
為什麼有些抗癌藥物能殺死癌細胞，卻仍難以阻止腫瘤轉移？關鍵可能不只在癌細胞本身，也與周圍的免疫環境密切相關。
中國醫藥大學江智聖副教授參與領導的研究團隊，在國際頂尖奈米科技期刊《ACS Nano》發表重要成果，開發出名為「FINAL」的新型奈米藥物平台，為癌症精準治療帶來新突破。
研究團隊將化療藥物「多西他賽」包覆於奈米載體，並利用天然海藻多醣「褐藻糖膠」修飾表面，使藥物能同時鎖定癌細胞與腫瘤相關巨噬細胞。
這項創新設計不僅提升藥物進入腫瘤的效率，更能調節免疫細胞功能、減少促進癌症轉移的細胞交互作用，並抑制腫瘤血管新生。
在三陰性乳癌動物實驗中，FINAL有效抑制腫瘤生長及肺部轉移，並使實驗動物的存活時間約增加一倍，同時減少部分傳統化療副作用。
這項研究展現奈米科技結合免疫調控與化學治療的潛力，為未來發展更精準、有效且安全的抗癌療法開啟新方向。
Making Cancer Treatment More Precise: CMU Researchers Develop a Dual-Targeting Nanomedicine for Advanced Immunochemotherapy
Why do some anticancer drugs successfully kill cancer cells but fail to prevent tumors from spreading? The answer may lie not only in cancer cells themselves but also in the complex immune environment surrounding tumors.
A research team co-led by Associate Professor Chih-Sheng Chiang of China Medical University (CMU) has published significant findings in the prestigious journal ACS Nano, introducing an innovative nanomedicine platform called FINAL that offers a promising new approach to precision cancer treatment.
The researchers developed a nanoparticle delivery system containing the chemotherapy drug docetaxel, with its surface modified using fucoidan, a natural marine polysaccharide derived from brown algae. This design enables the nanoparticles to simultaneously target cancer cells and tumor-associated macrophages through a protein called P-selectin.
Beyond improving targeted drug delivery, FINAL helps reshape the tumor microenvironment by regulating immune cell activity, disrupting interactions that promote cancer metastasis, and suppressing the formation of new blood vessels that support tumor growth.
In preclinical models of triple-negative breast cancer, FINAL significantly suppressed tumor growth and lung metastasis, approximately doubled animal survival time, and reduced certain toxic effects associated with conventional chemotherapy.
This breakthrough highlights the potential of combining nanotechnology, immune modulation, and chemotherapy to develop more precise, effective, and safer cancer treatments, opening promising new directions for next-generation cancer nanomedicine.
原文網址: https://pubs.acs.org/ancac3/article/20/18/13496/5084127/Concurrent-P-Selectin-Targeting-Nanoparticle
研究團隊｜Research Team
中文版
第一作者：李瑋
共同通訊作者：陳三元、鄭隆賓、徐偉成、江智聖
英文：
First Author: Wei Lee
Corresponding Authors: San-Yuan Chen, Long-Bin Jeng, Woei-Cherng Shyu, Chih-Sheng Chiang
相關圖片：
